Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.55 +0.20 (+0.58%)
Streaming Delayed Price Updated: 2:22 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,755,738
Open 33.40
Bid (Size) 33.54 (12)
Ask (Size) 33.55 (23)
Prev. Close 33.35
Today's Range 33.17 - 33.64
52wk Range 32.83 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 4.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry. 
Via Benzinga
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint. 
Via Benzinga

Performance

YTD
-10.57%
-10.57%
1 Month
-12.09%
-12.09%
3 Month
-19.84%
-19.84%
6 Month
-26.73%
-26.73%
1 Year
-5.19%
-5.19%

More News

Read More
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
Via Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
Via Investor's Business Daily
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
Via Benzinga
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Via Benzinga
Topics Government
Exposures Political
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
Via Investor's Business Daily
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Via Benzinga
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
From GSK plc
Via Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Via Benzinga
Exposures Product Safety
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
Via Benzinga
Exposures Product Safety
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
Via Benzinga
2 Best Artificial Intelligence Stocks to Buy in October
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Via Benzinga
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.